Following another rough quarter, NeuroMetrix has sought outside help in an effort to restructure its business and is pivoting away from a direct-to-consumer business model for its wearable pain relief platform, Quell.
“NeuroMetrix has good product lines and technology, and more broadly, the company has real value,” Dr. Shai Gozani, CEO and president of NeuroMetrix, told investors in a recent...
Laid to rest. A longstanding legal dispute between Apple and Valencell over infringement on four patents and deceptive trade practices was quietly put to bed last year. The two companies submitted their dismissal to the US District Court North Carolina in September, with no other details on how the settlement shook out.
When this case (and a similar one against Fitbit) was first filed in early...
Earnings reports shared by neurostimulation and digital medicine company NeuroMetrix during a Q2 investors’ call showed a slight drop in total revenue as the company is preparing to place its marketing weight behind the launch of its updated wearable pain relief product, Quell. However, the company remained profitable during the quarter thanks to sales of its other product, DPNCheck.
Dr. Shai N....
About the author: Naomi Fried, PhD (@NaomiFried), is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation infrastructure consulting to healthcare stakeholders including pharma companies and providers. Her previous positions include the first Chief Innovation Officer at Boston Children’s Hospital, Biogen’s VP of Innovation and External Partnerships, and VP...
Target has plans to launch a new digital health initiative next month online and in 500 of its 1,793 stores. Beyond knowing the stories will offer a new section for health devices, details on what, exactly, the launch will entail are scarce. One device that will be included is Quell, an FDA-cleared and smartphone-connected wearable for treating chronic pain from Waltham, Massachusetts-based...
